Close Menu
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
What's Hot

Trump administration sues judges over media comments | Civil Rights News

September 30, 2026

Valor, Atreides and Sequoia back AI startup Flow Engineering at $750 million valuation

September 30, 2026

Chinese factory activity ends two consecutive months of contraction in September

September 30, 2026
Facebook X (Twitter) Instagram
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Facebook X (Twitter) Instagram
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Home » Stocks with the biggest moves at midday: CCL, FICO, BE, IOVA
World

Stocks with the biggest moves at midday: CCL, FICO, BE, IOVA

Editor-In-ChiefBy Editor-In-ChiefSeptember 29, 2026No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email


Here are some companies that are making headlines in intraday trading. Carnival — Carnival shares rose 12% after the cruise company reported third-quarter profits that beat Wall Street expectations before the market opened. Management reported that bookings were strong despite the macro challenges facing consumers, noting that calendar year 2027 was booked at record occupancy rates, while occupancy rates and prices for 2028 were also higher year-over-year. Shares of Royal Caribbean and Norwegian Cruise Line also rose in line, rising 6% and about 4%, respectively. Ivans Biotherapeutics — Shares rose 26% after the cancer treatment-focused biotechnology company raised its full-year earnings outlook. Iovance’s revenue increased from $350 million to $370 million previously to $410 million to $420 million. Bloom Energy — Shares rose 13%. Jefferies kept its rating unchanged but raised its price target from $229 to $264, citing the energy company’s growth prospects. Additionally, the city of Fremont, Calif., posted on LinkedIn Friday that Bloom Energy has acquired a 158,000-square-foot facility for expansion. Artificial intelligence in action — Stock prices associated with AI-building efforts rose as investors bought up stocks. Lumentum’s share price rose 6%, while Nevius Group’s share price rose 4%. Coreweave stock rose nearly 2%. Oracle — The database management platform’s stock rose more than 5%. Oracle has debuted Fusion Claw, an agent application that “combines AI inference and deterministic enterprise calculations to enable highly complex tasks to be completed economically and at scale,” the company said in a statement. Fair Isaac — Shares fell 18% after Federal Housing Finance Agency Commissioner Bill Pruitt introduced mortgage pricing changes. “In response to feedback from lenders and consumers, we are simplifying mortgage pricing. Instead of two separate pricing grids that make no sense at all, Fannie and Freddie are adding VantageScore to the existing FICO Classic pricing grid. We are moving to a single pricing grid with the addition of…” Pulte said in a post on X. Bloomin’ Brands — shares of parent company Outback Steakhouse rose 3% after J.P. Morgan upgraded the company to neutral from underweight. The bank pointed to several changes the restaurant chain has implemented, including a new steak lineup and “reducing the table-to-server ratio from six tables to four tables during peak hours.” SpaceX — Shares rose 2% after TD Cowen initiated research coverage on the space company with a buy rating. Analysts pointed to growth in artificial intelligence and space exploration as SpaceX’s main drivers. Summit Therapeutics — Shares rose 5% after the drugmaker announced a $2 billion investment from AstraZeneca. “Summit has entered into an agreement with AstraZeneca for a strategic equity investment in Summit and a clinical collaboration focused on ivonecicimab and sonecitag vedotin (sone-ve),” Summit said in a release. Ibonecimab and Sonesitag Vedotin are drugs intended to treat cancer. CarMax — Shares rose more than 5% after the used car retailer reported better-than-expected second-quarter results. CarMax earned $1.16 per share on revenue of $7.88 billion. Analysts polled by FactSet expected revenue of $7.09 billion and earnings of 73 cents a share. —CNBC’s Nick Wells, Michelle Fox, Paulina Ricos, Scott Schnipper and Darla Mercado contributed reporting.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editor-In-Chief
  • Website

Related Posts

Chinese factory activity ends two consecutive months of contraction in September

September 30, 2026

CNBC Daily Open: Markets wide awake as September ends

September 30, 2026

Chinese government warns of retaliation if Europe imposes restrictions on Chinese companies

September 30, 2026
Add A Comment

Comments are closed.

News

Trump administration sues judges over media comments | Civil Rights News

By Editor-In-ChiefSeptember 30, 2026

Seven Minnesota judges are facing ethics charges for speaking publicly about the U.S. president’s immigration…

President Trump plans to announce $200 billion in energy investment from South Korea | Business and Economic News

September 30, 2026

US Federal Reserve watchdog certifies that there was no criminal activity in renovation costs during the Powell administration | Financial Market News

September 30, 2026
Top Trending

Valor, Atreides and Sequoia back AI startup Flow Engineering at $750 million valuation

By Editor-In-ChiefSeptember 30, 2026

Flow Engineering, a startup that provides AI tools for hardware design, has…

Restate wins $20M as AI agents drive need for durable infrastructure

By Editor-In-ChiefSeptember 30, 2026

When Stephan Ewen co-founded Restate in 2022 to provide durable workflow infrastructure,…

Andrew Feldman of Cerebras Systems attends Disrupt 2026

By Editor-In-ChiefSeptember 30, 2026

The capabilities of AI models continue to improve. But each leap requires…

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Welcome to WhistleBuzz.com (“we,” “our,” or “us”). Your privacy is important to us. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you visit our website https://whistlebuzz.com/ (the “Site”). Please read this policy carefully to understand our views and practices regarding your personal data and how we will treat it.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Facebook X (Twitter) Instagram Pinterest
  • Home
  • Advertise With Us
  • Contact US
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
  • About US
© 2026 whistlebuzz. Designed by whistlebuzz.

Type above and press Enter to search. Press Esc to cancel.